The present invention provides novel dihydropyrancarboxamide compounds of formula (I): ##STR00001## and collections of these compounds, and provides methods for the synthesis of these compounds; wherein R.sup.1 R.sup.6 are as defined herein. Additionally, the present invention provides pharmaceutical compositions and methods for treating disorders such as proliferative diseases, and cancer, to name a few.
Claims What is claimed is: 1. A compound having the structure: ##STR00104## or pharmaceutically acceptable salt, ester, or salt of such ester; wherein R.sub.1, R.sub.2 and R.sub.4 are each independently hydrogen or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety; R.sub.3 is an aryl moiety having one of the following structures: ##STR00105## R.sub.5 and R.sub.6 are each independently hydrogen or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, and wherein R.sub.5 and R.sub.6, taken together, may form a cyclic aliphatic, heteroaliphatic, aliphatic(aryl), heteroaliphatic(aryl), aliphatic(heteroaryl) or heteroaliphatic(heteroaryl) moiety, or an aryl or heteroaryl moiety; wherein each of the foregoing aliphatic and heteroaliphatic moieties may be substituted or unsubstituted, cyclic or acyclic, saturated or unsaturated or linear or branched; and each of the foregoing aryl, heteroaryl, alkylaryl or alkylheteroaryl moieties may be substituted or unsubstituted. 2. The compound of claim 1, wherein the compound has the structure (II): ##STR00106## or pharmaceutically acceptable salt, ester, or salt of such ester; wherein R.sub.1, R.sub.2 and R.sub.4 are each independently hydrogen or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety; R.sub.3 is an aryl moiety having one of the following structures: ##STR00107## R.sub.5 and R.sub.6 are each independently hydrogen or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, and wherein R.sub.5 and R.sub.6, taken together, may form a cyclic aliphatic, heteroaliphatic, aliphatic(aryl), heteroaliphatic(aryl), aliphatic(heteroaryl) or heteroaliphatic(heteroaryl) moiety, or an aryl or heteroaryl moiety; wherein each of the foregoing aliphatic and heteroaliphatic moieties may be substituted or unsubstituted, cyclic or acyclic, saturated or unsaturated or linear or branched; and each of the foregoing aryl, heteroaryl, alkylaryl or alkylheteroaryl moieties may be substituted or unsubstituted. 3. The compound of claim 1, wherein R.sup.1 is hydrogen or an alkyl, heteroalkyl, aryl or heteroaryl moiety substituted with Z, wherein Z is hydrogen, --(CH.sub.2).sub.qOR.sup.Z, --(CH.sub.2).sub.qSR.sup.Z, --(CH.sub.2).sub.qN(R.sup.Z).sub.2, --(C.dbd.O)R.sup.Z, --(C.dbd.O)N(R.sup.Z).sub.2, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, wherein q is 0 4, and wherein each occurrence of R.sup.Z is independently hydrogen, a protecting group, a solid support unit, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety; wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moieties may be substituted or unsubstituted. 4. The compound of claim 3, wherein R.sup.1 is hydrogen, lower alkyl, a substituted or unsubstituted phenyl or -(lower alkyl)phenyl moiety, --(CH.sub.2).sub.nOR.sup.Z, --[(CH.sub.2).sub.nO].sub.mR.sup.Z, --(CH.sub.2).sub.n--Ar--(CH.sub.2).sub.mOR.sup.Z; wherein n and m are each independently integers from 1 6, Ar represents a substituted or unsubstituted aryl or heteroaryl moiety, and R.sup.Z is independently hydrogen, a protecting group, a solid support unit, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety; wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moieties may be substituted or unsubstituted. 5. The compound of claim 4, wherein R.sup.1 is hydrogen, ethyl, or has one of the structures: ##STR00108## R.sup.z is as defined in claim 4. 6. The compound of claim 1, wherein R.sup.2 is hydrogen or an alkyl, heteroalkyl, aryl or heteroaryl moiety substituted with Z, wherein Z is hydrogen, --(CH.sub.2).sub.qOR.sup.Z, --(CH.sub.2).sub.qSR.sup.Z, --(CH.sub.2).sub.qN(R.sup.Z).sub.2, --(C.dbd.O)R.sup.Z, --(C.dbd.O)N(R.sup.Z).sub.2, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, wherein q is 0 4, and wherein each occurrence of R.sup.Z is independently hydrogen, a protecting group, a solid support unit, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -heteroaliphatic)heteroaryl moiety; wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moieties may be substituted or unsubstituted. 7. The compound of claim 6, wherein R.sup.2 is hydrogen, lower alkyl, a substituted or unsubstituted phenyl or -(lower alkyl)phenyl moiety, --(CH.sub.2).sub.nOR.sup.Z, --[(CH.sub.2).sub.nO].sub.mR.sup.Z, --(CH.sub.2).sub.n--Ar--(CH.sub.2).sub.mOR.sup.Z; wherein n and m are each independently integers from 1 6, Ar represents a substituted or unsubstituted aryl or heteroaryl moiety, and R.sup.Z is independently hydrogen, a protecting group, a solid support unit, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety; wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moieties may be substituted or unsubstituted. 8. The compound of claim 6, wherein R.sup.2 is hydrogen or has one of the structures: ##STR00109## wherein R.sup.z is as defined in claim 6. 9. The compound of claim 1, wherein R.sup.4 is hydrogen or an alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -heteroalkyl)heteroaryl moiety; wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -heteroalkyl)heteroaryl moieties may be substituted or unsubstituted. 10. The compound of claim 9, wherein R.sup.4 is hydrogen alkyl or heteroalkyl. 11. The compound of claim 1, wherein R.sup.5 and R.sup.6 are each independently hydrogen or an alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety; or wherein R.sup.5 and R.sup.6, taken together, form a substituted or unsubstituted, saturated or unsaturated cyclic moiety comprising 5 12 carbon atoms, 0 5 oxygen atoms, 0 5 sulfur atoms and 1 5 nitrogen atoms; and wherein each of the foregoing alkyl or heteroalkyl moieties may be substituted or unsubstituted, linear or branched, cyclic or acyclic, saturated or unsaturated; and wherein each of the foregoing aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -heteroalkyl)heteroaryl moieties may be substituted or unsubstituted. 12. The compound of claim 1, wherein --NR.sup.5R.sup.6 is one of the following the structures: ##STR00110## ##STR00111## 13. The compound of claim 1 having the structure: ##STR00112## 14. The compound of claim 1 having the structure: ##STR00113## 15. The compound of claim 1 having the structure: ##STR00114## 16. The compound of claim 1 having the structure: ##STR00115## 17. A library of compounds comprising a plurality of library members, wherein at least two library members are a compound of claim 1 or 2. 18. The library of claim 17, wherein the library comprises at least 100 compounds. 19. The library of claim 17, wherein the library comprises at least 1,000 compounds. 20. The library of claim 17, wherein the library comprises at least 2,000 compounds. 21. The library of claim 17, wherein the library comprises at least 10,000 compounds. 22. A pharmaceutical composition comprising: a compound of any one of claims 1, 2, 5, 8, 12, 13 15 and 16 and a pharmaceutically acceptable carrier. 